RAM
ALNY icon

Resona Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Resona Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
40,053
+221
+0.6% +$66.7K 0.06% 290
2026
Q1 		$13.1M Buy
39,832
+585
+1% +$199K 0.07% 261
2025
Q4 		$15.6M Sell
39,247
-2,250
-5% -$996K 0.08% 233
2025
Q3 		$18.9M Sell
41,497
-2,203
-5% -$897K 0.09% 208
2025
Q2 		$14.2M Buy
43,700
+4,780
+12% +$1.32M 0.07% 267
2025
Q1 		$10.5M Buy
38,920
+2,264
+6% +$582K 0.06% 286
2024
Q4 		$8.64M Sell
36,656
-921
-2% -$242K 0.05% 327
2024
Q3 		$10.3M Sell
37,577
-5,890
-14% -$1.53M 0.06% 296
2024
Q2 		$10.6M Sell
43,467
-3,474
-7% -$548K 0.06% 281
2024
Q1 		$7.02M Buy
+46,941
New +$7.83M 0.04% 378

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Resona Asset Management's ALNY Position: Q2 2026 in Review

Resona Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.55% in Q2 2026, buying an estimated $66.7K and bringing the position to 40,053 shares worth $12M. The position accounts for 0.06% of the portfolio, ranked #290.

Resona Asset Management first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. The position peaked at $18.9M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Resona Asset Management held 40,053 shares of Alnylam Pharmaceuticals worth $12M as of Q2 2026.
  • Resona Asset Management bought 221 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $66.7K.
  • Alnylam Pharmaceuticals made up 0.06% of Resona Asset Management's portfolio in Q2 2026, its #290 holding.
  • Resona Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Resona Asset Management's Alnylam Pharmaceuticals position peaked at $18.9M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Resona Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.